Quest Diagnostics Beats Q1, Raises FY Guidance

Quest Diagnostics reported Q1 FY2026 adjusted EPS $2.50, beating consensus $2.37, and revenue $2.90 bn, up 9.2% YoY.
Company raised FY2026 adjusted EPS guidance to $10.63‑$10.83 and revenue outlook to $11.78‑$11.90 bn, both above prior forecasts.
Shares climbed about 3% in pre‑market trading, with the stock up 2.90% after the earnings release.
Operating income rose 15.5% to $399 million, cash from operations fell 11.6% YoY to $278 million, capex $114 million.